Article Sidebar

Submitted
May 14, 2026
Accepted
Jun 7, 2026
Published
Jun 20, 2026
Download
pdf
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background: Cardiovascular disease is a major cause of morbidity and mortality, with treatment commonly involving polypharmacy, which increases the risk of drug interactions.


Methods: This study aimed to evaluate potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. This study used a descriptive observational design with a retrospective approach through prescription review. A total of 45 prescriptions that met the inclusion criteria were selected using total sampling. Data were analyzed descriptively using frequency and percentage.


Results: The results showed that most prescriptions contained 3–4 drugs (62.2%), indicating polypharmacy. A total of 92 potential drug interaction cases were identified, consisting of 79.30% pharmacodynamic interactions and 20.70% pharmacokinetic interactions. Pharmacokinetic interactions occurred during the absorption, distribution, metabolism, and excretion phases, with examples including digoxin–spironolactone, clopidogrel–lansoprazole, and metformin–furosemide. The most common interaction combinations occurred between cardiovascular drugs (54.35%).


Conclusion: In conclusion, there are potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. These findings highlight the importance of drug interaction screening in pharmaceutical services to improve the safety and effectiveness of therapy.

Keywords

Pharmacokinetics Drug interaction Polypharmacy

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite
Hidayati, M., & Rahmadevi, R. (2026). THE EVALUATION OF DRUG INTERACTIONS IN PRESCRIPTIONS FOR HEART DISEASE PATIENTS AT THE XYZ PHARMACY IN 2024: DRUG INTERACTIONS. INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 8(1), 195–203. https://doi.org/10.36566/ijhsrd/Vol8.Iss1/384

References

  1. 1. Aljadhey, H., et al. (2016). Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care, 28(4), 450–455.
  2. 2. Aronson, J. K. (2016). Meyler’s side effects of drugs: The international encyclopedia of adverse drug reactions and interactions (16th ed.). Elsevier.
  3. 3. Ayuningsih, I. (2022). Potensi kejadian interaksi obat pada pasien penyakit jantung koroner rawat jalan di RSKD Duren Sawit. Repository Poltekkes Kemenkes Jakarta II.
  4. 4. Badan Penelitian dan Pengembangan Kesehatan. (2018). Laporan Nasional Riskesdas 2018.
  5. 5. Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation, 139(10), e56–e528.
  6. 6. Crawford, C., Patel, J., & Hockings, L. (2019). Role of P-glycoprotein in cardiovascular drug interactions. Journal of Clinical Pharmacology, 59(9), 1175–1187.
  7. 7. Fajariyani, A., Mariyana, T., & Rachmawati, P. (2024). Kajian retrospektif potensi interaksi obat resep polifarmasi pada pasien poli jantung di Rumah Sakit X di Karawang. The Journal General Health and Pharmaceutical Sciences Research, 2(2), 08–16.
  8. 8. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., & Williams, K. M. (2016). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 55(1), 81–98.
  9. 9. Gurbel, P. A., & Tantry, U. S. (2014). Antiplatelet therapy and bleeding risk. Circulation, 129(25), 2686–2698.
  10. 10. Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2014). Predicting and manipulating cardiac drug inactivation by Eggerthella lenta. Science, 341(6143), 295–298.
  11. 11. Hilmer, S.N. & Gnjidic, D. (2018). The effects of polypharmacy in older adults. Clin Pharmacol Ther, 103(2), 186–188.
  12. 12. Islamiyah, A.N. (2021). Telaah Potensi Interaksi Obat Resep Polifarmasi Klinik Jantung pada Salah Satu Rumah Sakit di Bandung. Kartika: Jurnal Ilmiah Farmasi, 8(1), 25-35.
  13. 13. Kim, J., Lee, H., & Park, S. (2024). Impact of proton pump inhibitors on clopidogrel responsiveness and clinical outcomes: A systematic review. Biomedicines, 12(1), 115–128.
  14. 14. Li, X., Andersson, T. B., Ahlström, M., & Weidolf, L. (2021). Comparison of inhibitory effects of proton pump-inhibiting drugs on human cytochrome P450 activities. Frontiers in Pharmacology, 12, 694371.
  15. 15. Mangoni, A.A. & Jackson, S.H.D. (2017). Age-related pharmacokinetic and pharmacodynamic changes: basic principles and clinical relevance. Br J Clin Pharmacol, 83(6), 1036–1046.
  16. 16. Mengistie, Y. G., Bitew, H. B., Tuha, A., & Hailu, H. G. (2021).
  17. Assessment of Potential Drug–Drug Interactions and Their Predictors in Chronic Outpatient Department of Dessie Referral Hospital, Northeast Ethiopia. Drug, Healthcare and Patient Safety, 13, 29–35.
  18. 17. Midão, L., Giardini, A., Menditto, E., Kardas, P., & Costa, E. (2018). Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Archives of Gerontology and Geriatrics, 78, 213–220.
  19. 18. Mullish, B. H., Williams, H. R. T., & Marchesi, J. R. (2018). The gut microbiome and pharmacology. Clinical Medicine, 18(3), 224–227.
  20. 19. Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016). Drugs that may cause or exacerbate heart failure. Circulation, 134(6), e32–e69.
  21. 20. Palmer, B. F., & Clegg, D. J. (2019). Diuretics and potassium balance. The New England Journal of Medicine, 381(1), 60–72.
  22. 21. Radu, A.-F., Radu, A., Bungau, G. S., Tit, D. M., Vesa, C. M., Jurca, T., Uivarosan, D., Gitea, D., Brata, R., & Bustea, C. (2026). Polypharmacy and drug–drug interaction architecture in hospitalized cardiovascular patients: Insights from real-world analysis. Biomedicines, 14(1), 218.
  23. 22. Shi, S., Morike, K., & Klotz, U. (2020). The clinical implications of ageing for rational drug therapy. European Journal of Clinical Pharmacology, 76, 107–115.
  24. 23. Spanakis, M., Alexakis, K., & Ioannou, P. (2025). Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review. Frontiers in Pharmacology, 16, 1685710.
  25. 24. Stopfer, P., Giessmann, T., Hohl, K., Sharma, A., Ishiguro, N., Taub, M. E., Zimdahl-Gelling, H., Gansser, D., Wein, M., Ebner, T., & Mueller, F. (2016). Pharmacokinetic interaction between the MATE1 transporter inhibitor and metformin. Clinical Pharmacology & Therapeutics, 100(5), 482–492.
  26. 25. Suharyani, S. (2015). Evaluasi penggunaan kombinasi obat digoksin dan furosemid pada pasien gagal jantung. Jurnal Kesehatan, 6(2), 701–708.
  27. 26. Wedemeyer, R. S., & Blume, H. (2014). Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety, 37(4), 201–211.
  28. 27. Weir, M. R., & Rolfe, M. (2010). Potassium homeostasis and renin–angiotensin–aldosterone system inhibitors. Clinical Journal of the American Society of Nephrology, 5(3), 531–548.
  29. 28. World Health Organization. (2023). Cardiovascular diseases (CVDs).